Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia

Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis

(2021) R. Scott Wright et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Advances in familial hypercholesterolaemia in children

(2021) M Doortje Reijman et al.   Lancet Child & Adolescent Health

Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia

(2020) G. Kees Hovingh et al.   CIRCULATION

Worldwide Prevalence of Familial Hypercholesterolemia

(2020) Sabina O. Beheshti et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cognition After Lowering LDL-Cholesterol With Evolocumab

(2020) Baris Gencer et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

(2020) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

(2020) Frederick J. Raal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of Lowering Low-Density Lipoprotein Cholesterol with Contemporary Lipid-Lowering Medicines on Cognitive Function: A Systematic Review and Meta-Analysis

(2020) Hangying Ying et al.   CARDIOVASCULAR DRUGS AND THERAPY

Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trials

(2018) Jie Bai et al.   Journal of Clinical Lipidology

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

(2018) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cognitive Function in a Randomized Trial of Evolocumab

(2017) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

(2017) Kevin Fitzgerald et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intensive LDL-cholesterol lowering therapy and neurocognitive function

(2017) Maciej Banach et al.   PHARMACOLOGY & THERAPEUTICS

PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia

(2016) Matthew K. Ito et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment

(2015) Albert Wiegman et al.   EUROPEAN HEART JOURNAL

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

(2014) M. Cuchel et al.   EUROPEAN HEART JOURNAL

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

(2013) B. G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Blood sample volumes in child health research: review of safe limits

(2011) Stephen RC Howie   BULLETIN OF THE WORLD HEALTH ORGANIZATION